Novavax. has filed a patent for an adjuvant composition using Fraction A of Quil A with other adjuvants to enhance immune response synergistically. The composition includes saponins, lipopeptides, and derivatives like monophosphoryl lipid A. This innovation aims to boost the effectiveness of co-administered antigens or immunogens. GlobalData’s report on Novavax gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Novavax Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Novavax, Anti-RSV vaccines was a key innovation area identified from patents. Novavax's grant share as of January 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.

Adjuvant composition for enhancing immune response

Source: United States Patent and Trademark Office (USPTO). Credit: Novavax Inc

The filed patent (Publication Number: US20240024468A1) claims the use of fraction A of Quil A in combination with at least one other adjuvant to prepare an adjuvant composition with a synergistic effect. This composition is said to enhance immune responses and exhibit immunomodulating activity. Quil A is a saponin adjuvant known for its ability to boost the immune system's response to vaccines, making it a valuable component in adjuvant formulations. By combining fraction A of Quil A with other adjuvants, the patent aims to create a composition that not only enhances immune responses but also modulates the immune system's activity, potentially leading to improved vaccine efficacy.

The synergistic effect of using fraction A of Quil A with other adjuvants in the preparation of adjuvant compositions is a key aspect of the patent's claims. By leveraging the unique properties of Quil A and combining it with other adjuvants, the patent seeks to create a formulation that can significantly enhance the immune responses triggered by vaccines. This approach could potentially lead to the development of more effective vaccines that provide better protection against infectious diseases. The inclusion of fraction A of Quil A in adjuvant compositions could represent a promising advancement in the field of vaccine development, offering new possibilities for improving immune responses and overall vaccine efficacy.

To know more about GlobalData’s detailed insights on Novavax, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies